| Literature DB >> 32326881 |
Tolga Dittrich1, Stephan Marsch1,2, Adrian Egli2,3,4, Stephan Rüegg2,5, Gian Marco De Marchis2,5, Sarah Tschudin-Sutter2,6, Raoul Sutter7,8,9.
Abstract
BACKGROUND: Cerebrospinal fluid (CSF) analyses are recommended in patients with meningitis and/or encephalitis, but evidence regarding its diagnostic yield is low. We aimed to determine predictors of infectious pathogens in the CSF of adult patients presenting with meningitis, and/or encephalitis.Entities:
Keywords: Cerebrospinal fluid; Encephalitis; Meningitis; Meningoencephalitis; Neurocritical care
Mesh:
Year: 2020 PMID: 32326881 PMCID: PMC7181581 DOI: 10.1186/s12879-020-05022-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographics, initial principal diagnosis, infectious pathogens, and comorbidities of patients with meningitis and/or encephalitis with and without identified infectious pathogens
| Demographics and admission characteristics | Total cohort ( | Patients with identified pathogens ( | Patients without identified pathogens ( | ||||
|---|---|---|---|---|---|---|---|
| Age (years; median, IQR) | 54 | 36–71 | 58 | 38–72 | 51 | 35–70 | 0.217 |
| Male (n, %) | 215 | 57.8 | 85 | 53.5 | 130 | 61.0 | 0.143 |
| Referral from other hospital (n, %) | 101 | 27.2 | 39 | 24.5 | 62 | 29.1 | 0.326 |
| Admission via emergency room (n, %) | 324 | 87.1 | 139 | 87.4 | 185 | 86.8 | 0.872 |
| Suspected meningitis and/or encephalitis as reason of admission (n, %) | 262 | 70.4 | 113 | 71.1 | 149 | 69.9 | 0.815 |
| Glasgow coma score on day of diagnosis (median, IQR) | 14 | 7–15 | 13 | 4–15 | 14 | 11–15 | 0.004 |
| Meningitis (n, %) | 170 | 45.7 | 81 | 50.9 | 89 | 41.8 | 0.193 |
| Encephalitis (n, %) | 136 | 36.6 | 51 | 32.1 | 85 | 39.9 | |
| Meningoencephalitis (n, %) | 66 | 17.7 | 27 | 17.0 | 39 | 18.3 | |
| Bacterial (n, %) | 71 | 19.1 | 71 | 44.6 | |||
| 27 | 7.3 | 27 | 17.0 | ||||
| 14 | 3.8 | 14 | 8.8 | ||||
| 5 | 1.3 | 5 | 3.1 | ||||
| Others (n, %) ( | 25 | 6.7 | 25 | 15.7 | |||
| Viral (n, %) | 85 | 22.8 | 85 | 53.5 | |||
| 25 | 6.7 | 25 | 15.7 | ||||
| 22 | 5.9 | 22 | 13.8 | ||||
| 21 | 5.6 | 21 | 13.2 | ||||
| Others (n, %) ( | 17 | 4.6 | 17 | 10.7 | |||
| Protozoal (all | 3 | 0.8 | 3 | 1.9 | |||
| Charlson Comorbidity Index [ | 0 | 0–2 | 0 | 0–2 | 0 | 0–2 | 0.913 |
| Immunosuppression (n, %) | 111 | 29.8 | 58 | 36.5 | 53 | 24.9 | 0.017 |
| History of drug abuse (n, %) | 27 | 7.3 | 11 | 6.9 | 16 | 7.5 | 0.827 |
| History of prior CNS disorders (n, %) | 149 | 40.1 | 67 | 42.1 | 82 | 38.5 | 0.478 |
| Epileptic disorder (n, %) | 65 | 17.5 | 29 | 18.2 | 36 | 16.9 | 0.737 |
| Prior meningitis and/or encephalitis (n, %) | 28 | 7.5 | 15 | 9.4 | 13 | 6.1 | 0.228 |
| Prior autoimmune CNS disease (n, %) | 3 | 0.8 | 2 | 1.3 | 1 | 0.5 | |
| Prior Dementia (n, %) | 11 | 3.0 | 5 | 3.1 | 6 | 2.8 | |
| Prior leukoencephalopathy (n, %) | 46 | 12.4 | 22 | 13.8 | 24 | 11.3 | 0.457 |
| Prior stroke (n, %) | 23 | 6.2 | 4 | 2.5 | 19 | 8.9 | 0.015 |
| Prior intracranial hemorrhage (n, %) | 13 | 3.5 | 7 | 4.4 | 6 | 2.8 | 0.410 |
| Prior neurodegenerative disorder other than dementia (n, %) | 7 | 1.9 | 2 | 1.3 | 5 | 2.4 | |
| Prior brain tumor (n, %) | 8 | 2.2 | 7 | 4.4 | 1 | 0.5 | 0.023 |
IQR interquartile range, CNS central nervous system, CSF cerebrospinal fluid, FSME “Frühsommer”-Meningoenzephalitis; Bold-values indicate significance set at a-value of < 0.002 after correction for multiple comparisons (Bonferroni)
All continuous variables were analyzed using the Mann-Whitney U test
Fig. 1Flow chart. CSF = cerebrospinal fluid. 26.3% (n = 56) alternative CNS pathologies: 10 autoimmune/paraneoplastic encephalitides; 7 strokes; 3 intracranial hemorrhages; 3 traumatic brain injuries; 3 septic encephalopathies; 3 brain tumors; 3 prion diseases; 11 others
Blood cell counts and chemistry on day of diagnosis, neuroimaging, cerebrospinal fluid data, treatment characteristics, complications, and outcomes of patients with meningitis and/or encephalitis with and without identified infectious pathogens
| Total cohort ( | Patients with identified pathogens ( | Patients without identified pathogens ( | |||||
|---|---|---|---|---|---|---|---|
| White blood cell count (× 109/l; median, IQR) | 8.4 | 6.6–12.0 | 9.1 | 7.0–13.7 | 8.2 | 6.7–11.6 | 0.060 |
| C-reactive protein (mg/l; median, IQR) | 7.8 | 1.7–48.3 | 16.8 | 3.5–97.5 | 5.9 | 1.3–34.2 | 0.002 |
| Albumin (g/l; median, IQR) | 34 | 30–38 | 33 | 29–38 | 34 | 30–38 | 0.245 |
| Lactate (mmol/l; median, IQR) | 1.2 | 0.9–1.7 | 1.3 | 0.9–1.9 | 1.2 | 0.9–1.6 | 0.136 |
| Neuroimaging performed (n, %) | 335 | 90.1 | 140 | 88.1 | 195 | 91.6 | 0.265 |
| Computed tomography performed (n, %) | 247 | 66.4 | 112 | 70.4 | 135 | 63.4 | 0.154 |
| Magnetic resonance imaging performed (n, %) | 237 | 63.7 | 84 | 52.8 | 153 | 71.8 | |
| Brain lesions on neuroimaging in patients with imaging (n, % patients with imaging) | 203 | 4.6 | 92 | 65.7 | 111 | 56.9 | 0.104 |
| Brain edema in patients with imaging (n, % patients with imaging) | 39 | 10.5 | 19 | 13.6 | 20 | 10.3 | 0.351 |
| Brain inflammation in patients with imaging (n, % patients with imaging) | 68 | 18.3 | 35 | 25.0 | 33 | 16.9 | 0.070 |
| White blood cells (× 106/l; median, IQR) | 65 | 10–261 | 171 | 43–575 | 33 | 5–122 | |
| Polynuclear cells (×106/l; median, IQR) | 5 | 0.3–37.4 | 16 | 3–187 | 1 | 0–12 | |
| Mononuclear cells (×106/l; median, IQR) | 39 | 6–139 | 81 | 16–217 | 21 | 4–90 | |
| Protein (mg/l; median, IQR) | 807 | 497–1449 | 1650 | 629–2470 | 684 | 449–1111 | |
| Lactate (mmol/l; median, IQR) | 2.4 | 1.8–3.5 | 3 | 2.1–7.5 | 2.1 | 1.6–2.8 | |
| Glucose (mmol/l; median, IQR) | 3.2 | 2.6–3.8 | 2.9 | 1.9–3.5 | 3.3 | 2.9–3.9 | |
| Glucose ratio (CSF/serum; median, IQR) | 0.6 | 0.5–0.6 | 0.5 | 0.4–0.6 | 0.6 | 0.5–0.7 | |
| Hospital stay (days; median, IQR) | 11 | 5–19 | 14 | 6–21 | 9 | 4–17 | 0.015 |
| Treatment on ICUs (n, %) | 141 | 37.9 | 69 | 43.4 | 72 | 33.8 | 0.059 |
| ICU stay of patients in ICUs (days; median, IQR) | 3 | 2–7 | 4 | 2–7 | 3 | 2–7 | 0.208 |
| Mechanical ventilation (n, %) | 43 | 11.6 | 29 | 18.2 | 14 | 6.6 | |
| Empiric antimicrobial treatment (n, %) | 323 | 86.8 | 151 | 95.0 | 172 | 80.8 | |
| Antiseizure drugs (n, %) | 121 | 32.5 | 51 | 32.1 | 70 | 32.9 | 0.872 |
| Vasopressors (n, %) | 4411.8 | 28 | 17.6 | 16 | 7.5 | 0.003 | |
| Arterial hypotension (n, %) | 44 | 11.8 | 28 | 17.6 | 16 | 7.5 | 0.003 |
| Epileptic seizures (n, %) | 25 | 6.7 | 14 | 8.8 | 11 | 5.2 | 0.165 |
| Status epilepticus (n, %) | 20 | 5.4 | 7 | 4.4 | 13 | 6.1 | 0.643 |
| Aspiration pneumonia (n, %) | 13 | 3.5 | 6 | 3.8 | 7 | 3.3 | 0.785 |
| Brain herniation (n, %) | 6 | 1.6 | 4 | 2.5 | 2 | 0.9 | 0.408 |
| Death (n, %) | 11 | 3.0 | 3 | 1.9 | 8 | 3.8 | 0.365 |
| Care withdrawal (n, %) | 7 | 1.9 | 3 | 1.9 | 4 | 1.9 | 1.000 |
| Return to premorbid baseline (n, %) | 236 | 63.4 | 102 | 64.2 | 134 | 62.9 | 0.806 |
IQR interquartile range, ICU intensive care unit; Bold-values indicate significance set at a-value of < 0.002 after correction for multiple comparisons (Bonferroni)
All continuous variables were analyzed using the Mann-Whitney U test
Uni- and multivariable logistic regression models for the prediction meningitis and/or encephalitis with identified infectious pathogens by CSF parameters (excluding protozoal infections)
| Univariable | Multivariable | Hosmer-Lemeshow | Pearson’s | |||||||
| OR | 95% CI | OR | 95% CI | |||||||
| White blood cells (per106/l) | 1.00 | 0.99–1.00 | 0.283 | 1.00 | 0.99–1.00 | 0.141 | 13.50 | 0.096 | 305.7 | 0.321 |
| Protein (per mg/l) | 1.01 | 1.00–1.01 | 0.99 | 0.99–1.00 | 0.852 | |||||
| Lactate (per 0.1 mmol/l) | 1.29 | 1.18–1.42 | 1.11 | 0.93–1.34 | 0.254 | |||||
| Glucose ratio (per 0.1unit) | 0.01 | 0.01–0.06 | 0.05 | 0.01–0.37 | ||||||
| Univariable | Multivariable | |||||||||
| RR | 95% CI | RR | 95% CI | |||||||
| White blood cells (per106/l) | 1.00 | 1.00–1.01 | 0.58 | 0.18–1.89 | 0.368 | |||||
| Polynuclear cells (per 106/l) | 1.01 | 1.00–1.01 | 1.72 | 0.53–5.60 | 0.368 | |||||
| Mononuclear cells (per 106/l) | 1.01 | 1.00–1.01 | 1.72 | 0.53–5.61 | 0.367 | |||||
| Protein (per mg/l) | 1.01 | 1.00–1.01 | 1.00 | 0.99–1.00 | 0.982 | |||||
| Lactate (per 0.1 mmol/l) | 1.55 | 1.38–1.75 | 1.34 | 1.04–1.71 | ||||||
| Glucose ratio (per 0.1unit) | 0.01 | 0.00–0.01 | 0.01 | 0.00–0.17 | ||||||
| White blood cell count (per106/l) | 1.00 | 0.99–1.00 | 0.103 | 0.62 | 0.30–1.29 | 0.203 | ||||
| Polynuclear cells (per 106/l) | 0.99 | 0.99–1.00 | 0.208 | 1.61 | 0.77–3.33 | 0.204 | ||||
| Mononuclear cells (per 106/l) | 1.01 | 1.00–1.01 | 1.62 | 0.78–3.36 | 0.198 | |||||
| Protein (per mg/l) | 1.00 | 0.99–1.00 | 0.634 | 1.00 | 1.00–1.00 | 0.925 | ||||
| Lactate (per 0.1 mmol/l) | 1.02 | 0.87–1.18 | 0.830 | 1.00 | 0.76–1.30 | 0.997 | ||||
| Glucose ratio (per 0.1unit) | 0.09 | 0.01–0.60 | 0.10 | 0.10–1.02 | 0.052 | |||||
| Forward selection | Backward selection | Hosmer-Lemeshow | Pearson’s | |||||||
| RR | 95% CI | RR | 95% CI | |||||||
| White blood cells (per106/l) | NS | NS | ||||||||
| Polynuclear cells (per 106/l) | NS | NS | ||||||||
| Mononuclear cells (per 106/l) | NS | NS | ||||||||
| Protein (per mg/l) | NS | NS | ||||||||
| Lactate (per 0.1 mmol/l) | 1.35 | 1.12–1.64 | 1.35 | 1.12–1.64 | 6.58 | 0.583 | 135.8 | 0.14 | ||
| Glucose ratio (per 0.1unit) | 0.01 | 0.00–0.23 | 0.10 | 0.00–0.23 | ||||||
| White blood cell count (per106/l) | NS | NS | ||||||||
| Polynuclear cells (per 106/l) | NS | NS | ||||||||
| Mononuclear cells (per 106/l) | 1.01 | 1.00–1.01 | 1.01 | 1.00–1.01 | 9.46 | 0.305 | 194.1 | 0.39 | ||
| Protein (per mg/l) | NS | NS | ||||||||
| Lactate (per 0.1 mmol/l) | NS | NS | ||||||||
| Glucose ratio (per 0.1unit) | NS | NS | ||||||||
CSF cerebrospinal fluid, OR odds ratio, CI confidence interval, NS not selected
Bold-values indicate significance set at < 0.05
Fig. 2Receiver operating characteristic analyses for the prediction of meningitis and/or encephalitis with identified infectious pathogens by CSF parameters (excluding protozoal infections). CSF = cerebrospinal fluid